# The temporal sequence of myasthenia gravis and neuromyelitis optica spectrum disorder: a case report and systematic review of 74 patients

**Authors:** Zhenyu Niu, Yi Bao, Lanqiu Yao, Jingru Ren, Jianchun Wang, Jing Guo, Nan Zhang, Feng Gao, Hongjun Hao, Siwei Chen, Ran Liu

PMC · DOI: 10.3389/fneur.2026.1747855 · Frontiers in Neurology · 2026-02-13

## TL;DR

This study examines 74 cases where myasthenia gravis and neuromyelitis optica spectrum disorder co-occurred, finding that myasthenia gravis often precedes the other condition by years.

## Contribution

The study identifies a consistent temporal sequence and suggests a shared autoimmune predisposition between the two disorders.

## Key findings

- MG onset significantly preceded NMOSD onset in 93.2% of cases, with a mean interval of 12.56 years.
- Complement C5 inhibitor eculizumab showed marked clinical improvement in a patient unresponsive to steroids.

## Abstract

The co-occurrence of myasthenia gravis (MG) and neuromyelitis optica spectrum disorder (NMOSD) is rare, and their temporal sequence and shared pathogenesis remain poorly understood.

We present the case of a 43-year-old woman with pre-existing acetylcholine receptor antibody (AChR-Ab) positive ocular MG who developed aquaporin-4 antibody (AQP4-Ab) positive NMOSD. Additionally, we conducted a systematic literature review up to July 2024 to identify similar cases.

Including the present case, 74 patients were analyzed. The cohort showed a marked female predominance (89.2%). MG onset significantly preceded NMOSD onset in most patients (93.2%), with a younger mean age at onset (28.19 vs. 41.02 years, p < 0.001) and a mean interval of 12.56 years. Among tested patients, AChR-Ab was positive in 90.5% and AQP4-Ab in 73.0%. In our case, administration of the complement C5 inhibitor eculizumab led to marked clinical improvement after failure of high-dose steroid therapy.

This study suggests a consistent temporal pattern wherein MG predominantly precedes NMOSD, often by years, suggesting a possible shared autoimmune predisposition. The observed response to eculizumab highlights complement pathway inhibition as a potentially effective therapeutic strategy for this complex overlap syndrome, warranting further investigation.

## Linked entities

- **Proteins:** AQP4 (aquaporin 4)
- **Diseases:** myasthenia gravis (MONDO:0009688), neuromyelitis optica spectrum disorder (MONDO:0019100)

## Full-text entities

- **Genes:** C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, AQP4 (aquaporin 4) [NCBI Gene 361] {aka MIWC, MLC4, WCH4, hAQP4}, FCGRT (Fc gamma receptor and transporter) [NCBI Gene 2217] {aka FCRN, FcgammaRn, alpha-chain}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, C5 (complement C5) [NCBI Gene 727] {aka C5D, C5a, C5b, CPAMD4, ECLZB}, MOG (myelin oligodendrocyte glycoprotein) [NCBI Gene 4340] {aka BTN6, BTNL11, MOGIG2, NRCLP7}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}
- **Diseases:** hiccups (MESH:D006606), paraneoplastic (MESH:D010257), numbness (MESH:D006987), glial fibrillary acidic protein astrocytopathy (MESH:D001254), pruritus (MESH:D011537), ptosis (MESH:C564553), MG (MESH:D009157), neck pain (MESH:D019547), vomiting (MESH:D014839), severely impaired left-eye visual acuity (MESH:D001523), immune dysregulation (OMIM:614878), hyperreflexia (MESH:D012021), ON (MESH:D009902), neuromuscular junction dysfunction (MESH:D020511), multiple sclerosis (MESH:D009103), COVID-19 infection (MESH:D000086382), weakness (MESH:D018908), herpes zoster (MESH:D006562), Tumor (MESH:D009369), Devic's disease (MESH:D009471), autoimmune neurological disorders (MESH:D020274), demyelination in the central nervous system (MESH:D003711), thymic hyperplasia (MESH:D013952), hypokalemia (MESH:D007008), TM (MESH:D009188), thymoma (MESH:D013945), deterioration of vision (MESH:D014786), diplopia (MESH:D004172), constipation (MESH:D003248), immune-mediated disorders (MESH:C567355), urinary retention (MESH:D016055), membrane (MESH:D015433), injury (MESH:D014947), myelitis (MESH:D009187), inflammatory (MESH:D007249), thymic pathology (MESH:D013953), gastrointestinal symptoms (MESH:D012817), sensorimotor deficits (MESH:D020233), decreased muscle tone (MESH:D009123), autoimmune (MESH:D001327), autoimmune overlap syndromes (MESH:D000080445)
- **Chemicals:** AZA (MESH:D001379), folate (MESH:D005492), efgartigimod (MESH:C000718373), Eculizumab (MESH:C481642), homocysteine (MESH:D006710), rituximab (MESH:D000069283), ravulizumab (MESH:C000629409), vitamin B12 (MESH:D014805), satralizumab (MESH:C000655944), NA (MESH:D012964), pyridostigmine (MESH:D011729), mycophenolate mofetil (MESH:D009173), IVMP (-), Methylprednisolone (MESH:D008775), steroid (MESH:D013256)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945749/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945749/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945749/full.md

---
Source: https://tomesphere.com/paper/PMC12945749